|Table of Contents|

Long non-coding RNA 00628 affects cisplatin sensitivity of lung adenocarcinoma cells by TOP2A

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 02
Page:
197-205
Research Field:
Publishing date:

Info

Title:
Long non-coding RNA 00628 affects cisplatin sensitivity of lung adenocarcinoma cells by TOP2A
Author(s):
XIE Fei1; 2; WANG Zhaoxia1
1.Department of Oncology,the Second Affiliated Hospital of Nanjing Medical University,Jiangsu Nanjing 210011,China;2.Department of Oncology,the Fourth Affiliated Hospital of Nanjing Medical University,Jiangsu Nanjing 210031,China.
Keywords:
lung adenocarcinoma; long non-coding RNA 00628; cisplatin
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.02.001
Abstract:
Objective:To investigate the effect of long non-coding RNA (lncRNA) 00628 on cisplatin sensitivity of lung adenocarcinoma cells and its possible molecular mechanism.Methods:The different expression of lncRNAs in lung adenocarcinoma tissues and adjacent normal tissues were screened by database.CCK-8,clone formation,Transwell and flow cytometry were used to investigate the biological function of lung adenocarcinoma cells,and the effect of linc00628 on cisplatin sensitivity of lung adenocarcinoma cells was studied in vitro and vivo test.TOP2A,the downstream target gene of linc00628,was screened by RNA sequencing and verified by qRT-PCR and Western blot.The effect of TOP2A on cisplatin sensitivity of lung adenocarcinoma cells was investigated in vitro.Results:linc00628 was highly expressed in lung adenocarcinoma tissues and cells.Down-regulating linc00628 can enhance cisplatin sensitivity of lung adenocarcinoma cells in vitro and in vivo.TOP2A was the downstream target gene of linc00628.In vitro,downregulation of TOP2A enhanced cisplatin sensitivity in lung adenocarcinoma cells.Conclusion:linc00628 is highly expressed in lung adenocarcinoma tissues and cells.Down-regulation of linc00628 may enhance cisplatin sensitivity of lung adenocarcinoma cells by inhibiting TOP2A expression.

References:

[1] SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
[2] DAVID SE,WALLACE A,HOSSEIN B,et al.Non-small cell lung cancer,version 2.2013［J］.J Natl Compr Canc Netw,2013,11(6)：645-653.
[3] YIN YZ,YAO SH,LI CG,et al.Systematic analysis using a bioinformatics strategy identifes SFTA1P and LINC00519 as potential prognostic biomarkers for lung squamous cell carcinoma［J］.Am J Transl Res,2021,13(1)：168-182.
[4] CHEN J,JIANG F,HU LJ,et al.lncRNA RP11-838N2.3 promoted cisplatin resistance in lung adenocarcinoma［J］.Biomed Res Int,2020,2020：2806042.
[5] PIGNON JP,TRIBODET H,SCAGLIOTTI GV,et al.Lung adjuvant cisplatin evaluation：a pooled analysis by the LACE Collaborative Group［J］.Journal of Clinical Oncology,2008,26(21)：3552-3559.
[6] AMABLE L.Cisplatin resistance and opportunities for precision medicine［J］.Pharmacol Res,2016,106：27-36.
[7] BROZOVIC A,OSMAK M.Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin resistance［J］.Cancer Lett,2007,251(1)：1-16.
[8] GALLUZZI L,SENOVILLA L,VITALE I,et al.Molecular mechanisms of cisplatin resistance［J］.Oncogene,2012,31(15)：1869-1883.
[9] RANCOULE C,GUY JB,VALLARD A,et al.50th anniversary of cisplatin［J］.Bull Cancer,2017,104(2)：167-176.
[10] ZAROGOULIDIS K,ZAROGOULIDIS P,DARWICHE K,et al.Treatment of non-small cell lung cancer (NSCLC)［J］.Journal of Thoracic Disease,2013,5(Supplement 4)：S389-S396.
[11] KELLAND LR.Preclinical perspectives on platinum resistance［J］.Drugs,2000,59 (Suppl 4)：1-8.
[12] KOBERLE B,TOMICIC MT,USANOVA S,et al.Cisplatin resistance：preclinical findings and clinical implications［J］.Biochim Biophys Acta,2010,1806(2)：172-182.
[13] KIM C,KANG D,LEE EK,et al.Long noncoding RNAs and RNA-binding proteins in oxidative stress,cellular senescence,and age-related diseases［J］.Oxid Med Cell Longev,2017,2017：2062384.
[14] SCHMITZ SU,GROTE P,HERRMANN BG.Mechanisms of long noncoding RNA function in development and disease［J］.Cell Mol Life Sci,2016,73(13)：2491-2509.
[15] CORRA F,AGNOLETTO C,MINOTTI L,et al.The network of non-coding RNAs in cancer drug resistance［J］.Front Oncol,2018,8：327-351.
[16] 王海玲，李东霞.LncRNA与恶性肿瘤侵袭转移研究进展［J］.现代肿瘤医学，2018,26（13）：2114-2117. WANG HL,LI DX.Advances in the research of LncRNA and invasion and metastasis of malignant tumor［J］.Modern Oncology,2018,26（13）：2114-2117.
[17] ZHANG MC,ZHANG L,ZHANG MQ,et al.Downregulated LINC00628 aggravates the progression of colorectal cancer via inhibiting p57 level［J］.Eur Rev Med Pharmacol Sci,2020,24(4)：1763-1770.
[18] HE R,WU JX,ZHANG Y,et al.LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma［J］.Eur Rev Med Pharmacol Sci,2018,22(18)：5857-5866.
[19] CHEN Q,WANG D,LI Y,et al.LINC00628 suppresses migration and invasion of hepatocellular carcinoma by its conserved region interacting with the promoter of VEGFA［J］.J Cell Physiol,2019,234(9)：15751-15762.
[20] XU SF,ZHENG Y,ZHANG L,et al.Long non-coding RNA LINC00628 interacts epigenetically with the LAMA3 promoter and contributes to lung adenocarcinoma［J］.Mol Ther Nucleic Acids,2019,18：166-182.
[21] CHEN DQ,ZHENG XD,CAO Y,et al.Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer［J］.Eur Rev Med Pharmacol Sci,2017,21(2)：275-283.
[22] WOODARD GA,JONES KD,JABLONS DM.Lung cancer staging and prognosis［J］.Cancer Treat Res,2016,170：47-75.
[23] O' KANE GM,BREDBURY PA,FELD R,et al.Uncommon EGFR mutations in advanced non-small cell lung cancer［J］.Lung Cancer,2017,109：137-144.
[24] DENISENKO TV,BUDKEVICH IN,ZHIVOTOVSKY B.Cell death-based treatment of lung adenocarcinoma［J］.Cell Death Dis,2018,9(2)：117-130.
[25] DASARI S,TCHOUNWOU PB.Cisplatin in cancer therapy：molecular mechanisms of action［J］.Eur J Pharmacol,2014,740：364-378.
[26] PIGNON JP,TRIBODET H,SCAGLIOTTI GV,et al.Lung adjuvant cisplatin evaluation：a pooled analysis by the LACE collaborative group［J］.J Clin Oncol,2008,26(21)：3552-3559.
[27] FENNELL DA,SUMMERS Y,CADRANEL J,et al.Cisplatin in the modern era：the backbone of first-line chemotherapy for non-small cell lung cancer［J］.Cancer Treat Rev,2016,44：42-50.
[28] ZHANG Q,WEI Y,YAN Z,et al.The characteristic landscape of lncRNAs classified by RBP-lncRNA interactions across 10 cancers［J］.Mol Biosyst,2017,13(6)：1142-1151.
[29] ZHANG X,HONG R,CHEN W,et al.The role of long noncoding RNA in major human disease［J］.Bioorg Chem,2019,92：103214.
[30] EVANS JR,FENG FY,CHINNAIYAN AM.The bright side of dark matter：lncRNAs in cancer［J］.J Clin Invest,2016,126(8)：2775-2782.
[31] WANG T,LU J,WANG R,et al.TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p［J］.J Cancer,2022,13(2)：589-601.
[32] ZHANG F,WU H.MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells［J］.Biochem Biophys Res Commun,2021,570：154-161.
[33] WANG B,SHEN Y,ZOU Y,et al.TOP2A promotes cell migration,invasion and epithelial-mesenchymal transition in cervical cancer via activating the PI3K/AKT signaling［J］.Cancer Manag Res,2020,12：3807-3814.
[34] GAO Y,ZHAO H,REN M,et al.TOP2A promotes tumorigenesis of high-grade serous ovarian cancer by regulating the TGF-beta/Smad pathway［J］.J Cancer,2020,11(14)：4181-4192.
[35] GONG MC,CHEN WQ,JIN ZQ,et al.Prognostic value and significant pathway exploration associated with TOP2A involved in papillary thyroid cancer［J］.Int J Gen Med,2021,14：3485-3496.
[36] JIAN M,ZHANG L,HE M,et al.TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma［J］.Endocr Relat Cancer,2013,20(3)：361-370.
[37] KOU F,SUN H,WU L,et al.TOP2A promotes lung adenocarcinoma cells' malignant progression and predicts poor prognosis in lung adenocarcinoma［J］.J Cancer,2020,11(9)：2496-2508.
[38] ZHANG S,JIANG H,XU Z,et al.The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition［J］.Am J Cancer Res,2019,9(10)：2233-2248.
[39] BOUCHALOVA K,CIZKOVA M,CWIERTKA K,et al.Triple negative breast cancer-current status and prospective targeted treatment based on HER1 (EGFR),TOP2A and C-MYC gene assessment［J］.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2009,153(1)：13-17.
[40] LUAN S,GAO Y,LIANG X,et al.Aconitine linoleate,a natural lipoditerpenoid alkaloid,stimulates anti-proliferative activity reversing doxorubicin resistance in MCF-7/ADR breast cancer cells as a selective topoisomerase II alpha inhibitor［J］.Naunyn Schmiedebergs Arch Pharmacol,2022,395(1)：65-76.
[41] HONGO H,KOSAKA T,SUZUKI Y,et al.Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways［J］.Sci Rep,2021,11(1)：22284-22293.
[42] ZHU C,ZHANG L,ZHAO S,et al.UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer［J］.Cell Death Dis,2021,12(6)：519-533.

Memo

Memo:
National Natural Science Foundation of China(No.81871871）；国家自然科学基金资助项目（编号：81871871）
Last Update: 1900-01-01